- Home
- ALGS vs RAND Comparison
ALGS vs RAND Comparison
Compare ALGS & RAND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ALGS | RAND |
|---|---|---|
| Founded | 2018 | 1969 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.6M | 30.6M |
| IPO Year | 2020 | 1996 |
Fundamental Metrics
Financial Performance| Metric | ALGS | RAND |
|---|---|---|
| Price | $5.57 | $10.65 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $39.33 | N/A |
| AVG Volume (30 Days) | ★ 48.7K | 4.3K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 10.83% |
| EPS Growth | ★ 88.30 | N/A |
| EPS | N/A | ★ 0.34 |
| Revenue | ★ $2,186,000.00 | N/A |
| Revenue This Year | $32.20 | N/A |
| Revenue Next Year | $4.71 | N/A |
| P/E Ratio | ★ N/A | $31.32 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.98 | $10.00 |
| 52 Week High | $13.69 | $17.49 |
Technical Indicators
Market Signals| Indicator | ALGS | RAND |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 51.01 |
| Support Level | N/A | $10.58 |
| Resistance Level | N/A | $11.31 |
| Average True Range (ATR) | 0.00 | 0.27 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 0.00 | 37.11 |
Price Performance
Historical ComparisonAbout ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
About RAND Rand Capital Corporation
Rand Capital Corp is a closed-end, externally managed, non-diversified investment company. Its investment objective is to generate current income and, when possible, complement its current income with capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. It predominantly invests in higher-yielding debt instruments.